# SELLAS Life Sciences Group, Inc.: Biotechnology Research, New York, United States

> SELLAS Life Sciences Group, Inc.: We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer...

Source: https://millionrounds.com/startup/sellas-life-sciences-group-inc (Millionrounds; every figure on the page links to its filing or article)

United States · [Biotechnology Research startup](https://millionrounds.com/companies)

# SELLAS Life Sciences Group, Inc.

We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications.

Funding reported Last round: Post ipo equity

Biotechnology Research New York, United States

Company summary

- **Founded:** 2012 14 years old
- **Team:** 20 11 to 50 people
- **Funding reported:** $102M in dollars
- **Last round:** Post ipo equity Jul 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for SELLAS Life Sciences Group, Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About SELLAS Life Sciences Group, Inc.

We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications.

SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.

## What company datasets say SELLAS Life Sciences Group, Inc. raised

Funding, as reported

Reported in all **$102M** in dollars

Rounds **7**

Last round **Post ipo equity**

Last round date **Jul 2024**

## Founders and team

From SELLAS Life Sciences Group, Inc.'s own website and the SEC filings it signed: 4 on the team.

- **Andrew Elnatan** Senior Vice President, Regulatory Affairs, CMC, and Quality
- **Angelos M. Stergiou** Executive Officer, Director i
- **John T. Burns** Executive Officer i
- **Katherine Bach Kalin** Board of Directors

On the board, as filed i *David A. Scheinberg* *Jane Van Wasman* *John Van Varian* *Robert Van Nostrand*

## Biotechnology Research in United States

Startups like it

- [**Apeel Sciences** Goleta · founded 2012](https://millionrounds.com/startup/apeel-sciences)
- [**Insilico Medicine** Boston · founded 2014](https://millionrounds.com/startup/insilico-medicine-2)
- [**Tidal Vision** Bellingham · founded 2015](https://millionrounds.com/startup/tidal-vision)
- [**MyoKardia** Brisbane · founded 2012](https://millionrounds.com/startup/myokardia)
- [**Artax Biopharma Inc** Cambridge · founded 2013](https://millionrounds.com/startup/artax-biopharma-inc)
- [**Thrive Bioscience, Inc.** Beverly · founded 2014](https://millionrounds.com/startup/thrive-bioscience-inc)
- [**HistoWiz** Brooklyn · founded 2012](https://millionrounds.com/startup/histowiz)
- [**StemoniX** Maple Grove · founded 2014](https://millionrounds.com/startup/stemonix)

## Is this your company?

Add your raise, your deck and your story, and put SELLAS Life Sciences Group, Inc. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)